PRC
LGND icon

Pearl River Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Pearl River Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,724
Closed -$242K – 622
2019
Q4 		$242K Buy
+3,724
New +$249K 0.09% 411
2019
Q1 		– Sell
-481
Closed -$41K – 585
2018
Q4 		$41K Buy
+481
New +$51.3K 0.19% 147

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Pearl River Capital's LGND Position: Q1 2020 in Review

Pearl River Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2020, closing a stake of 3,724 shares — an estimated $242K sold.

Pearl River Capital first reported a position in LGND in Q4 2018 and held it in 2 quarters. The position peaked at $242K in Q4 2019. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2020.

  • Pearl River Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Pearl River Capital sold 3,724 Ligand Pharmaceuticals shares in Q1 2020, an estimated $242K.
  • Pearl River Capital first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Pearl River Capital's Ligand Pharmaceuticals position peaked at $242K in Q4 2019.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2020.

Based on Pearl River Capital's 13F filing for Q1 2020, filed 6 May 2020.